Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: fulvestrant|DRUG: sorafenib tosylate
Sponsor: OHSU Knight Cancer Institute
Collaborators: National Cancer Institute (NCI)